ONC-2010-31-A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma
Brief description of study
The goal of this randomized phase II trial is to evaluate the effect of Sorafenid adjuvant therapy in high risk patients following Orthotopic Liver Transplantion (OLT) with Hepatocellular Carciona.
Clinical Study Identifier: 11-01612
ClinicalTrials.gov Identifier: NCT11-01612
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
